|
 The company said on Thursday that it would use the data to discuss a
potential late-stage trial of the drug, ELND005, with the U.S. Food
and Drug Administration.
The company said in June that the large study did not reduce
moderate-to-severe agitation and aggression, pushing its U.S.-listed
shares down as much as 20 percent that day.
The latest analysis identified a sub-group within those patients,
who reacted positively to the drug.
ELND005 is the lead experimental drug that Transition Therapeutics
is testing. The Canadian developer has also completed a mid-stage
study of the drug in Down Syndrome patients.
Transition Therapeutics' U.S.-listed shares closed at $1.93 on
Wednesday. The stock has fallen about 20 percent since the company
reported initial results in June.
(This story has been corrected to fix typo in first paragraph.)
(Reporting by Vidya L Nathan in Bengaluru; Editing by Don Sebastian
and Anil D'Silva)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
